| |
 |
Synthesis of Quinazolines as Tyrosine Kinase Inhibitors
|
| |
|
pp.246-275 (30) Authors: Sanjay K. Srivastava, Vivek Kumar, Shiv K. Agarwal, Rama Mukherjee, Anand C. Burman |
| |
|
|
| |
|
A Trojan Horse in Drug Development: Targeting of Thapsigargins Towards Prostate Cancer Cells
|
| |
|
pp.276-294 (19) Authors: S. Brogger Christensen, Dorthe Mondrup Skytte, Samuel R. Denmeade, Craig Dionne, Jesper Vuust Moller, Poul Nissen, John T. Isaacs |
| |
|
|
| |
|
Quantification Techniques and Biodistribution of Semiconductor Quantum Dots
|
| |
|
pp.295-303 (9) Authors: Emilie Pic, Lina Bezdetnaya, Francois Guillemin, Frederic Marchal |
| |
|
|
| |
|
Novel Analogues of CC-1065 and the Duocarmycins for the Use in Targeted Tumour Therapies
|
| |
|
pp.304-325 (22) Authors: Lutz F. Tietze, Birgit Krewer |
| |
|
|
| |
|
The Management of Metastatic Bone Disease with the Combination of Bisphosphonates and Radiotherapy: From Theory to Clinical Practice
|
| |
|
pp.326-335 (10) Authors: V. Vassiliou, D. Kardamakis |
| |
|
|
| |
|
Antimitotic Chalcones and Related Compounds as Inhibitors of Tubulin Assembly
|
| |
|
pp.336-347 (12) Author: Sylvie Ducki |
| |
|
|
| |
|
Mechanisms of Trastuzumab Resistance in Breast Cancer
|
| |
|
pp.348-355 (8) Authors: Sara M. Tolaney, Ian E. Krop |
| |
|
|
| |
|
Current Development of Pd(II) Complexes as Potential Antitumor Agents
|
| |
|
pp.356-368 (13) Authors: Enjun Gao, Cong Liu, Mingchang Zhu, Huakuan Lin, Qiong Wu, Lei Liu |
| |
|
|
